Natixis Investment Managers International’s BioMarin Pharmaceuticals BMRN Stock Holding History

Natixis Investment Managers International’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,456	Closed	-$2.11M	–	267
2022 Q2	$2.11M	Buy	25,456 +22,924	+905%	+$1.83M	0.04%	124
2022 Q1	$195K	Buy	+2,532	New	+$212K	﹤0.01%	434
2018 Q4	–	Sell	-4,605	Closed	-$447K	–	96
2018 Q3	$447K	Buy	4,605 +484	+12%	+$48.3K	0.02%	495
2018 Q2	$388K	Buy	+4,121	New	+$361K	0.02%	472
2015 Q4	–	Sell	-3,882	Closed	-$409K	–	407
2015 Q3	$409K	Buy	3,882 +727	+23%	+$97.1K	0.06%	229
2015 Q2	$432K	Buy	+3,155	New	+$391K	0.05%	229

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Natixis Investment Managers International's BMRN Position: Q3 2022 in Review

Natixis Investment Managers International sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 25,456 shares — an estimated $2.11M sold.

Natixis Investment Managers International first reported a position in BMRN in Q2 2015 and held it in 6 quarters. The position peaked at $2.11M in Q2 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Natixis Investment Managers International reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Natixis Investment Managers International sold 25,456 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $2.11M.
Natixis Investment Managers International first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Natixis Investment Managers International's BioMarin Pharmaceuticals position peaked at $2.11M in Q2 2022.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Natixis Investment Managers International's 13F filing for Q3 2022, filed 14 Nov 2022.